.jpg)
After Yes - Navigating the Rules of the Road in Today's Marketplace
Panel Session
Regulatory, Quality and Good Manufacturing Practices
Sandra Cohen Kalter, JD
Vice President and Chief Regulatory Counsel
Medtronic
Richard Cleland
Assistant Director, Advertising Practices, Bureau of Consumer Protection
Federal Trade Commission
Lisa Dwyer
Partner, FDA and Life Sciences
King & Spalding
Eric Boyles
Senior Director, Global Digital and Social Media Team
Medtronic
Jeanne Mell
VP Corporate Communications
OraSure Technologies, Inc.
Twitter. Facebook. Instagram. Social media platforms have transformed how individuals and corporations are communicating and sharing information. These and other burgeoning social media tools can provide medtech companies new opportunities to effectively interact with patients, physicians, employees and other stakeholders. However, as a highly-regulated industry, medtech companies must consider this evolving media landscape in the context of FDA/FTC guidance and work to develop ways to maximize use of the these new social media tools that don't run afoul of regulators.
In this session, participants will gain an overview of how FDA/FTC regulates medtech company communications in the age of social media. Attendees will also learn about AdvaMed’s recently updated Direct-to-Consumer Advertising Industry Principles and how they can help companies establish processes in compliance with current regulations. Finally, representatives from medtech companies with active social media presences will provide case studies on how they have successfully utilized these new communications platforms. A Q&A session with all panel participants will conclude the session.
